Streetbeat News

Analyst Ratings

BWA

Morgan Stanley analyst Adam Jonas has maintained an Overweight rating on BorgWarner (NYSE:BWA) but lowered the price target from $50 to $47.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 1:45 pm

FWONA

Benchmark analyst Matthew Harrigan has reiterated a 'Buy' rating on Liberty Formula One Group (NASDAQ:FWONA) and maintained a price target of $77.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 1:43 pm

SWKS

Mizuho analyst Vijay Rakesh maintains a 'Buy' rating on Skyworks Solutions (NASDAQ:SWKS) but lowers the price target from $125 to $122.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 08, 2023 | 1:41 pm

BNTX

Morgan Stanley analyst Matthew Korn has maintained an Equal-Weight rating on BioNTech (NASDAQ:BNTX) and lowered the price target from $119 to $116.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 1:41 pm

APP

Benchmark analyst Mark Zgutowicz maintains a 'Sell' rating on AppLovin (NASDAQ:APP) and raises the price target from $14 to $17.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 08, 2023 | 1:40 pm

AYX

JMP Securities analyst Patrick Walravens maintains a Market Outperform rating on Alteryx (NYSE:AYX) but lowers the price target from $95 to $60.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 08, 2023 | 1:39 pm

HBI

Wedbush analyst Tom Nikic has reiterated a Neutral rating on Hanesbrands (NYSE:HBI) and maintained a price target of $5.5.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 1:38 pm

VTGN

VistaGen Therapeutics Inc's stock is trading lower after a 675% surge on Monday following the announcement of positive results from its Phase 3 PALISADE-2 trial of fasedienol nasal spray for adults with social anxiety disorder. The trial met primary and secondary endpoints, marking the first positive U.S. Phase 3 study of a therapy for social anxiety disorder in over 15 years. Maxim Group analyst Jason McCarthy upgraded VistaGen from Hold to Buy and set a $30 price target.

Portfolio Pulse from Adam Eckert

August 08, 2023 | 1:35 pm

RCUS

Morgan Stanley analyst Terence Flynn has maintained an Overweight rating on Arcus Biosciences (NYSE:RCUS) but lowered the price target from $40 to $38.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 1:33 pm

APO

Morgan Stanley analyst Michael Cyprys has maintained an Equal-Weight rating on Apollo Global Management (NYSE:APO) and raised the price target from $81 to $88.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 1:31 pm